Search results
3 No-Brainer Stocks to Buy for Under $100 Right Now
Motley Fool via Yahoo Finance· 21 hours agoPfizer built a massive cash stockpile when its COVID-19 vaccine sales were booming, and it has been putting that money to work. The company...
Pfizer Lingers Near 11-Year Low Despite Promising Cancer Drug Updates — Is It A Sell?
Investor's Business Daily· 3 days agoAt the midpoints, earnings would climb more than 22% as sales rise almost 3%. Pfizer Stock And...
Kansas attorney general sues Pfizer over COVID vaccine, company responds
KSNT Topeka· 6 days agoRelated video: Class action lawsuits – what are they, and should you join one? TOPEKA (KSNT) –...
Kansas Attorney General Kris Kobach sues Pfizer over marketing of COVID-19 vaccine
The Kansas City Star· 6 days agoKansas Attorney General Kris Kobach is suing the pharmaceutical company Pfizer, alleging it deceptively marketed its COVID-19 vaccine. The lawsuit, filed ...
Kansas Attorney General Kris Kobach sues Pfizer for COVID-19 vaccine
WIBW Topeka· 6 days agoKansas Attorney General Kris Kobach on Monday morning announced he is suing Pfizer for what he said...
Marcum Wealth LLC Buys 3,926 Shares of Pfizer Inc. (NYSE:PFE)
ETF DAILY NEWS· 20 hours agoMarcum Wealth LLC boosted its stake in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 11.8% during the first quarter, according to the company in its most recent filing ...
3 No-Brainer Stocks to Buy for Under $100 Right Now
The Motley Fool via AOL· 21 hours agoPfizer built a massive cash stockpile when its COVID-19 vaccine sales were booming, and it has been putting that money to work. The company acquired...revenue ...
Apella Capital LLC Trims Stock Position in Pfizer Inc. (NYSE:PFE)
ETF DAILY NEWS· 21 hours agoApella Capital LLC decreased its holdings in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 3.0% during the 1st quarter, according to its most recent 13F filing with the ...
Better High-Yield Dividend Stock: Pfizer vs. Bristol Myers Squibb
Motley Fool via Yahoo Finance· 5 days agoWith a trailing 12-month payout ratio of 443%, Pfizer doesn't have a lot of room for error on this...
Merck wins FDA OK for vaccine rival to Pfizer’s pneumococcal shot
BioPharma Dive via Yahoo Finance· 5 days agoThe advisory committee is set to meet on June 27. Merck set the price of Capvaxive at $287 per the...